Advanced search    

Search: authors:"Precious Takondwa Makondi"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Development of novel predictive miRNA/target gene pathways for colorectal cancer distance metastasis to the liver using a bioinformatic approach

(DEGs) between GSE49355, GSE41258 and GSE81558. (XLSX) 15 / 20 Author Contributions Conceptualization: Po-Li Wei, Yu-Jia Chang. Data curation: Precious Takondwa Makondi, Po-Li Wei, Chien-Yu Huang, Yu ... -Jia Chang. Formal analysis: Precious Takondwa Makondi, Po-Li Wei, Yu-Jia Chang. Funding acquisition: Yu-Jia Chang. Investigation: Precious Takondwa Makondi, Yu-Jia Chang. Methodology: Precious

Bromelain inhibits the ability of colorectal cancer cells to proliferate via activation of ROS production and autophagy

Huang. Data curation: Tung-Cheng Chang, Po-Li Wei, Precious Takondwa Makondi, Chien-Yu Investigation: Tung-Cheng Chang, Po-Li Wei, Wei-Ting Chen, Chien-Yu Huang. Methodology: Precious Takondwa Makondi ... . Writing ? original draft: Po-Li Wei, Chien-Yu Huang, Yu-Jia Chang. Writing ? review & editing: Tung-Cheng Chang, Precious Takondwa Makondi, Yu-Jia 15 / 18 16 / 18 17 / 18 2015; 4:e08941. https://doi.org

Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer

. Data curation: Precious Takondwa Makondi, Chia-Hwa Lee, Yu-Jia Chang. Investigation: Precious Takondwa Makondi, Chi-Ming Chu, Po-Li Wei. S2 Table. Up-regulated genes. (DOCX) Author Contributions Formal ... analysis: Chi-Ming Chu. Funding acquisition: Po-Li Wei. Methodology: Chi-Ming Chu. Project administration: Yu-Jia Chang. Resources: Yu-Jia Chang, Po-Li Wei. Software: Precious Takondwa Makondi

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer

Background Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is SN-38) is one of the significant obstacles in the treatment of advanced colorectal cancer (CRC). The molecular mechanism or targets mediating irinotecan resistance are still unclear. It is urgent to find the irinotecan response biomarkers to improve CRC patients’ therapy...